Fairvalue-Calculator Fairvalue-Calculator
EN DE

Phathom Pharmaceuticals, Inc (PHAT) Fair Value & Analysis

Healthcare · US · Market cap $868M

Price$10.69
Fair Value$7.68
Upside-28.2%
Quality95/100
Evidence: Low Range $5.76 – $9.61

Fair value as of: Jun 23, 2026

Analysis

Phathom Pharmaceuticals, Inc (PHAT) currently trades at $10.69, while our model-based Fair Value estimate is $7.68 — implying the stock looks roughly 28.2% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -38% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +1% Alnylam Pharmaceuticals, Inc (ALNY) -63%

Frequently asked questions

Is Phathom Pharmaceuticals, Inc (PHAT) undervalued?
As of Jun 23, 2026, our model estimates a fair value of $7.68 versus a price of $10.69 — about −28% (overvalued). Model-based estimate, not financial advice.
What is the fair value of PHAT?
Our 21-model fair value for Phathom Pharmaceuticals, Inc is $7.68 (as of Jun 23, 2026), built from audited fundamentals. The current price is $10.69.
What is the quality score of PHAT?
Phathom Pharmaceuticals, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.